NO SHOW JOBS 🤌

Tuesday, April 14, 2026 | 9:00 AM PST

Your daily edge. The Consigliere delivers.

Market Snapshot

📊 Live Quotes — Tuesday Session

VIX

18.38

▼ 3.87%

Dow

48,532

▲ 0.65%

S&P 500

6,948

▲ 0.90%

Nasdaq

23,510

▲ 1.41%

$AMZN

$247.48

▲ 3.16%

$GOOG

$328.46

▲ 2.90%

$NVDA

$193.45

▲ 2.19%

$RXRX

$3.53

▲ 3.07%

Market Tone: Yesterday we told the family the market wanted to go higher. Today it's doing exactly that. S&P 500 through 6,948 (+0.90%), Nasdaq ripping +1.41%, Dow green +0.65%, VIX collapsing nearly 4% to 18.38. AMZN +3.16% on the Globalstar deal. GOOG +2.90% as the DeepMind cancer story leaks into broader sentiment. NVDA +2.19%. The bears are covering. The sidelined cash is rotating in. This is what a market "wanting to go higher" looks like when it finally gets permission. And underneath the tape, there's a second story today bigger than any one-day move: the biggest disease in human history just got its most important breakthrough, and it came from an AI.

Bada Bing 🎯

Google DeepMind Just Used AI to Find a Cancer Drug. Yale Confirmed It Works.

On April 7, Google DeepMind and Yale published something the mainstream financial press almost completely ignored. An AI model discovered a new cancer therapy pathway, predicted which drug combination would work, and then a wet lab at Yale confirmed the prediction was correct.

Read that again. The AI didn't help scientists. The AI told scientists what to try. And it was right.

The model is called C2S-Scale. It's a 27 billion parameter foundation model for single-cell analysis, built on Google's open-source Gemma family. DeepMind and Yale scientists gave it a problem that has stumped oncologists for 30 years: most tumors are "cold." They're invisible to the body's immune system. The entire field of immunotherapy has been trying to make tumors "hot" so the immune system can attack them.

C2S-Scale was asked to find a drug that would amplify immune signals in tumors where small amounts of interferon were already present but too weak to trigger a response. It searched through cellular behavior data at a scale no human researcher could process. It came back with a specific answer: silmitasertib combined with interferon.

Yale took the prediction into a lab. Ran the experiment. The drug combination worked. Antigen presentation amplified. Cold tumors became hot. Immune system activated. A pathway no one had found in 30 years of cancer research, discovered by an AI in what amounted to a virtual screen.

This is not a press release. This is a preprint on bioRxiv. The model and resources are live on Hugging Face and GitHub right now. Researchers can build on it today.

27B parameters

C2S-Scale model size. Built on Google's Gemma. The first AI to independently discover a cancer therapy pathway and have it validated in a real wet lab. Released open source on Hugging Face and GitHub.

Here's why this matters more than Wall Street is pricing in.

The pattern of AI-discovered cancer therapies is accelerating fast. Insilico Medicine, another AI-first biotech, just advanced its AI-designed CDK12/13 inhibitor toward clinical trials for treatment-resistant cancers. Johns Hopkins' Kimmel Cancer Center is using AI to compress drug discovery from a decade and a billion dollars down to years and a fraction of the cost. AI-designed DNA drugs just demonstrated targeted delivery in Nature Biotechnology last month. The AACR is forecasting 2026 as the year AI becomes the default design tool across almost every major pharmaceutical company's oncology pipeline.

Translation: the gap between "AI-assisted drug discovery" and "AI-driven drug discovery" just closed. We are now in the era where AI models, not humans, are generating the hypotheses that become the drugs. Humans are running the validation trials. That is a fundamental shift in how cancer gets treated, and the cost curve is going to collapse.

Here's the contrarian angle the family needs to hear. The obvious trade is to buy small-cap biotech names and hope one lands an AI discovery that hits clinical trials. That's a lottery ticket. The real trade is the infrastructure layer: the companies that get paid whether the drug works or not, on every single AI-driven discovery, across every single biotech lab.

$GOOG is the belle of the ball today. DeepMind just proved Alphabet's AI research operation can do things no other company's AI has done: discover a previously unknown cancer pathway and have it validated in a real lab. GOOG is up nearly 3% to $328.46 today. The market is starting to notice but not obsessing yet. That comes later, when the second and third wet-lab validations hit.

$NVDA is the pick-and-shovel play. C2S-Scale was trained on NVIDIA GPUs. Insilico's models run on NVIDIA GPUs. Every major pharma company's internal AI drug discovery lab runs on NVIDIA hardware. Every hyperscaler that serves these models to researchers runs on NVIDIA infrastructure. NVDA up +2.19% to $193.45 today. No AI drug discovery happens without NVIDIA. Not a single validated hit. Not a single clinical trial. Not a single FDA submission. Every breakthrough is an NVIDIA invoice.

For the speculative tier of the portfolio, $RXRX, Recursion Pharmaceuticals, is the pure-play AI drug discovery biotech. RXRX runs its own wet labs, generates its own data, trains its own AI models on NVIDIA hardware, and is in a formal partnership with NVIDIA itself. Trading at $3.53 today, up +3.07%. High risk, high leverage to the thesis. One validated clinical hit and the stock is a different company.

The biggest disease in human history is being solved by the companies the family already owns. Cold tumors are turning hot. AI is writing the prescriptions. And the arms dealers are getting paid on every shot fired.

The family is watching. 🤌

📺 Watch today's breakdown on TikTok: tiktok.com/@noshowjobs

The Skim

Fact → So What → $Ticker

Amazon Acquires Globalstar in $11.57B Deal. Starlink Gets a Real Competitor. Apple Signs On.

Amazon announced today a definitive agreement to acquire Globalstar for $11.57 billion, $90 per share cash or 0.321 shares of AMZN stock, 117% premium from pre-rumor levels. The deal closes in 2027 and turbocharges Project Kuiper, now rebranded as Amazon Leo, into a real challenger to SpaceX Starlink in low-earth orbit. Buried in the announcement: Apple and Amazon signed a separate agreement where Amazon Leo will power iPhone and Apple Watch satellite features including Emergency SOS, Messages via satellite, and Find My. Apple just formally partnered with Amazon instead of building its own constellation. AMZN ripping +3.16% on the news.

Google DeepMind C2S-Scale Validated in Yale Wet Lab. AI Discovered New Cancer Pathway.

DeepMind and Yale published the biggest AI drug discovery proof point to date on April 7. C2S-Scale, a 27 billion parameter Gemma-based model, predicted that silmitasertib plus interferon would amplify antigen presentation in "cold" tumors. Yale confirmed it in the lab. The AI was right. Model and code released open source. GOOG up +2.90% to $328.46 today. Full breakdown in today's Bada Bing.

Goldman Sachs Calls Software Oversold. IGV Down 30% YTD, Cheapest Relative Valuation in a Decade.

Goldman's Peter Oppenheimer published a note yesterday saying tech sector underperformance "is starting to generate attractive opportunities for investors." Software's premium to the broader market has fallen to its lowest level in roughly 10 years. The iShares Expanded Tech-Software ETF (IGV) is down 30% year-to-date through April 10. Microsoft reports earnings April 29 with the stock down 21% YTD heading in. If Azure growth stabilizes and guidance holds, MSFT is set up for a classic "oversold mega-cap bounces on non-terrible earnings" move.

OpenAI vs Musk Trial Starts April 27. Anthropic Quietly Embeds Claude Into Microsoft Word.

Two fast-moving AI industry stories. OpenAI accused Elon Musk of attempting a "legal ambush" with improper proposals weeks before their April 27 trial over OpenAI's transition from nonprofit to for-profit. Result either way reshapes AI industry governance. Separately, Anthropic launched Claude for Word in beta, adding AI drafting, editing, tracked changes, and clickable citations inside Microsoft Word for Team and Enterprise users. Third Office integration after Excel and PowerPoint. Anthropic is quietly embedding into the entire Microsoft productivity stack while OpenAI deals with legal distractions.

Waste Management 🗑️

Everyone Betting Against AI Is Missing the Biggest Disruption in Pharma History.

For two years, the bearish AI thesis has been the same recycled talking point: "AI is overhyped. It's just fancy autocomplete. Real breakthroughs still require humans. Real science still requires wet labs. Real drugs still require clinical trials."

Google and Yale just blew that thesis to pieces.

C2S-Scale didn't assist a human researcher. It replaced one. The model was given a problem, searched through biological data at a scale no human could process, and came back with a specific, testable, previously unknown hypothesis. Yale's job was to confirm the AI was right. And it was.

That's not autocomplete. That's discovery.

The bearish reframing is already starting. "Well, it still needed a lab to confirm it." "Well, silmitasertib was already a known compound." "Well, interferon therapy is decades old." All true. All irrelevant. The breakthrough is not the compounds. The breakthrough is the AI knowing which combination would work when no human did.

Here's what happens next. Every major pharma company is now racing to build or buy equivalents of C2S-Scale. Pfizer, Merck, Novartis, Roche, AstraZeneca: they will all have internal AI drug discovery programs running on NVIDIA hardware within 18 months. Some already do. The ones that don't will be acquiring AI biotechs at premium multiples to catch up. Insilico Medicine, Recursion, Isomorphic Labs, BenevolentAI, and a dozen others will either IPO into euphoric markets or get bought outright.

The picks-and-shovels play compounds. Every pharma internal lab needs GPUs. Every acquisition target was trained on GPUs. Every validation study requires more GPUs. The $NVDA thesis isn't about one drug. It's about being the infrastructure layer under the entire AI-native drug discovery era.

And the mega-cap narrative is shifting in real time. Google was getting dinged in 2024 and 2025 as "losing the AI race to OpenAI and Anthropic." DeepMind was supposedly the research arm that produced cool papers but no business value. Then DeepMind solved protein folding with AlphaFold. Then it won a Nobel Prize for it. Now it just demonstrated that its models can discover cancer drugs human researchers missed. At some point Wall Street is going to reprice Alphabet as the dominant AI-science company on earth, and the current $328 price is going to look quaint.

The bears will be wrong the way they were wrong about semiconductors in 2023, wrong about power infrastructure in 2024, and wrong about nuclear restarts in 2025. The family doesn't wait for Wall Street to catch up. The family buys the names that are already working.

Cold tumors are turning hot. AI is writing the prescriptions. And the family is positioned for every shot fired.

The Family Ledger 📖

One Prediction. Timestamped. Immutable.

New Prediction

AI-driven drug discovery becomes the dominant narrative in large-cap tech and biotech sector flows over the next 12 months. $GOOG re-rates higher as Wall Street recognizes DeepMind's scientific AI moat is structurally different from the OpenAI/Anthropic consumer-chatbot race. Over the next 90 days, GOOG trades above $360 at least once. $NVDA remains the best-positioned infrastructure play and trades above $215 in the same window. $RXRX, the speculative pure-play, trades above $5.00 within 180 days on any single credible clinical-stage AI drug discovery announcement.

⚠️ Not investment advice. Do your own research. The family has positions in names mentioned.

🤖 Powered by AI. Edited by The Consigliere.

📧 Forward this to one trader you know. That's how the family grows. 🤌

noshowjobs.net · @NoShowJobs